NL-OMON44819招募中不适用
owering infliximab dose in IBD patients in remission, based on infliximab trough levels: the study on Lowering Infliximab in IBD patients in sustained Remission, the LIR study - LIR-study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age 18 or above
- •Written informed consent
- •Patients with ulcerative colitis or ileocolonic Crohn*s disease, treated with infliximab (IFX), dosed at 5mg/kg, regardless of dosing interval
- •In sustained clinical remission for at least 12 months whilst being treated with infliximab
- •Full clinical response and disease control, defined as
- •-Absence of intestinal or extra-intestinal symptoms, as judged by both patient and physician
- •-Fecal calprotectin < 250 µg/g and CRP within normal range
排除标准
- •Concomitant corticosteroid usage
- •Imminent need for IBD-related surgery
- •Actively draining perianal fistula
- •Pregnancy or lactation
- •Other significant medical illness that might interfere with this study (such as current malignancy, immunodeficiency syndromes and psychiatric illness)
研究者
相似试验
进行中（未招募）
1 期
Adjusting the amount of medication (infliximab) in patients suffering from inflammatory bowel disease, using medication levels in blood.Crohns diseaseUlcerative colitisMedDRA version: 19.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 19.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-002651-15-NLZon MW
尚未招募
不适用
Adjusting infliximab dose in patients with inflammatory bowel disease, based on blood levels.Inflammatory Bowel Disease, in remission with infliximab treatment.NL-OMON27672Erasmus MC Rotterdam40
进行中（未招募）
不适用
Infliximab dosing based on blood concentrations in patients with sarcoidosis: smart dosingSarcoidosisEUCTR2014-002224-26-NLSt. Antonius Hospital
撤回
4 期
A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment1002766510024967SarcoidosisNL-OMON42033Sint Antonius Ziekenhuis70
已完成
不适用
oss of response to infliximab in patients with intractable ulcerative colitis: Clinical features and outcomes.ulcerative colitisJPRN-UMIN000016640Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine40